SILCOPHL Silco Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 15.4 as of 2026-11-12 14:07:03
Rank 219 of all scored
Data completeness 100%
Data completeness 100%
Score breakdown
Consistency 50
Profitability 6
Solvency 100
Valuation 35
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency Paid a dividend every year (5/5)
- Solvency Practically debt-free (loan risk cannot hurt it)
- Valuation Trades near book value (P/NAV 0.66x)
Concerns
- Consistency EPS rose in only 0 of 4 years (erratic or cyclical)
- Profitability Average ROE only 2.62% (below 10%: capital not working hard)
- Profitability Net profit shrinking 15.75% a year
- Valuation P/E 46.67 is high (above 20)
Risk flags
- Category B (low or irregular dividends)
- Small cap (< Tk 200 cr): most exposed to manipulation and volatility
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
38.7% above the low, 33.9% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 35.3%
- Institution 16.8%
- Public 47.9%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 0.82 | 21.85 | 8 | 10 | 0 |
| 2022 | 0.81 | 21.95 | 8 | 5 | 0 |
| 2023 | 0.67 | 22.35 | 7 | 3 | 0 |
| 2024 | 0.44 | 22.66 | 5 | 1 | 0 |
| 2025 | 0.41 | 23.02 | 4 | 1.1 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 0%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.